Clinical Trials Browser

Withdrawn × Neoplasms × obinutuzumab × Clear all

NCT02611908 2019-01-25

Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02371590 2018-02-23

Lenalidomide and Obinutuzumab for Previously Untreated CLL

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell